Warhound Valued at $1.2 Billion After Raising $200 Million

Warhound emerged from stealth mode on Thursday with a valuation of $1.2 billion following a $200 million funding round. The new venture, which seeks to genetically engineer working dogs for the U.S. military and law enforcement, secured capital from a group of investors that includes Sequoia, 8VC, Corner Ventures, and In-Q-Tel. In-Q-Tel is a venture firm supported by the CIA and other U.S. intelligence agencies. The company was founded by Ben Lamm of Colossal Biosciences and Palmer Luckey of Anduril.

The startup targets a specific gap in the defense market. According to its launch materials, more than 80 percent of the U.S. military's working dogs are currently sourced from Europe. Furthermore, fewer than half of those imported animals are deemed fit for service. Warhound intends to reverse this trend by developing dogs with genetic traits tailored for demanding missions, reducing the nation's reliance on foreign breeding programs.

Lamm and Luckey met approximately one year ago at a conference where the need for improved military working dogs was discussed. Lamm subsequently researched breeding practices and identified common inherited issues that cause dogs to fail training, such as poor eyesight, cancer, hip dysplasia, and muscle atrophy. The team plans to use cell lines from high-performing breeds, including the Belgian Malinois and German Shepherd, stored in a biobank. They will edit these genes to enhance health, longevity, speed, and olfactory capabilities.

Anduril will play a critical role in the venture by providing hardware and software solutions. The company will supply equipment such as protective vests and goggles designed to improve situational awareness for both the dogs and their handlers. Lamm described the concept as adding technology on top of the dog rather than altering its biology, citing examples like bulletproof vests with data sensors that transmit real-time information to handlers. This approach aims to make the animals safer and more effective in the line of duty.

Colossal Biosciences, which is known for its de-extinction projects involving animals like the mammoth and dodo, holds equity in Warhound. The company supports the venture by licensing its gene cloning technology. Viagen, another firm owned by Colossal, will partner with Warhound to clone the dogs. Lamm noted that Viagen's technology offers a high success rate, a capability already utilized in Colossal's endangered species programs.

The first batch of dogs is currently being cloned and incubated, with births expected in early 2027. The company aims to have these animals in service within two years. While specific pricing has not been determined, Warhound expects to sell to first responders, the Department of Defense, military service groups, and police forces. Lamm stated that the company has briefed numerous government groups regarding its operations.

To address concerns about civilian safety and animal welfare, Warhound is working under the guidance of the American Humane Society. The society will help certify the training program for the new dogs. Upon retirement, the animals are expected to enter the society's Military Working Dog Reunification Program or other available support programs. The American Humane Society issued a statement expressing support for the collaboration, noting that it looks forward to ensuring the animals are treated humanely.

Luckey serves as a partner in the venture but does not hold equity in the company. The project represents a significant intersection of biotechnology and defense hardware, aiming to create a new type of dog that is genetically optimized for performance and equipped with advanced technological gear.